

ONLINE SUPPLEMENTARY DATA

Supplementary Table 1. Demographics, clinical characteristics of 32 patients with Behçet's disease treated with alemtuzumab.


N	Sex	Age	Organ involvement	Previous therapies	Disease duration (months)	No. of ALM courses	First ALM treatment	Remission	Relapse	Duration of remission (months)	Thyroid disease
1	M	39	OGU, E, S, GIT, J, L	Pred, AZA, CyA, CYC, Thal, PE, IVIG	14	3	1994	No	NA	NA	No
2	F	28	OGU, E, J, CNS	-	1	1	1998	Yes	No	172	No
3	F	14	OGU, S, CNS	Pred	43	1	1998	Yes	No	106	No
4	F	23	OGU, E, S, GIT, J, CNS	Pred, AZA, Tac	6	5	1998	Yes	Yes	34	No
5	M	35	OGU, E, GIT, Vasc	Pred, AZA, MMF, CyA, CYC, Thal	8	1	1998	Yes	Yes	7	No
6	F	30	OGU, E, GIT, J	Pred, AZA, CyA, MTX, Thal, IVIG	46	1	1998	Yes	No	82	Yes
7	F	42	OGU, J, S	Pred	3	1	1998	Yes	No	3	No
8	F	32	OGU, E, S, J	Pred, AZA, CyA, MTX, Thal, IVIG	101	3	1998	Yes	Yes	13	No
9	M	59	OGU, S, GIT, J, Vasc	Pred, CyA, CYC	2	1	1998	Yes	No	166	No
10	M	29	OGU, E, S, CNS	-	6	3	1998	Yes	Yes	43	No
11	M	25	OGU, E	Pred, Dap	1	1	1998	Yes	No	15	No
12	F	14	OGU, S, J, Vasc	Pred, AZA, CyA, Hcxq, TNF	84	3	1998	Yes	No	168	Yes
13	F	35	OGU, E, GIT, J, CNS	Pred, MMF, CyA, Tac, Thal	41	2	1999	Yes	Yes	21	Yes

14	F	39	OGU, E, S, GIT, J	Pred, AZA, MMF, CyA, Hcxq	14	1	1999	Yes	Yes	10	Yes
15	F	36	OGU, S, J, PNS	Pred	9	1	1999	Yes	No	178	No
16	F	33	OGU, E, GIT, CNS, PNS	Pred, MTX	332	1	1999	Yes	No	66	No
17	F	26	OGU, E, S, J, Vasc	Pred, AZA, Thal, Col	187	1	1999	No	NA	NA	No
18	F	49	OGU, S, J, CNS	PE	0	1	1999	Yes	Yes	10	Yes
19	F	19	OGU, E, S, J	Pred, AZA, Tac, Hcxq	31	2	2003	Yes	Yes	36	No
20	F	33	OGU, E, S, J, CNS, Vasc	Pred, MMF, CyA, Tac, Thal, Col, IVIG	15	2	2003	Yes	Yes	15	No
21	F	39	OGU, E, S, J, CNS	Pred, MMF, Tac, Thal, Col, Hcxq, TNF	121	4	2005	Yes	Yes	8	Yes
22	F	19	OGU, J, CNS, S	Pred, Tac, Col, Hcxq, IVIG, TNF	48	1	2006	No	NA	NA	Yes
23	M	43	OGU, E, S, CNS, Vasc	Pred, AZA, Tac, MTX, Thal, Hcxq, IVIG	162	1	2006	Yes	Yes	23	No
24	F	33	OGU, E, S, GIT, J	TNF, RIT	24	5	2007	Yes	Yes	15	Yes
25	M	47	OGU, J, K, L, S	Pred, AZA, Hcxq, TNF	23	2	2008	No	NA	NA	No
26	F	32	OGU, S, GIT, J, CNS	Pred, AZA, Hcxq, TNF	27	3	2011	No	NA	NA	No
27	F	26	OGU, S, J	AZA, MMF, Tac,	166	1	2011	Yes	Yes	5	No


				Col, Hcxq, TNF, Dap							
28	F	25	OGU, E, S, GIT, J, L, CNS, PNS	Pred, AZA, MMF, CYC, MTX, Thal, Col, Hcxq, TNF, RIT	184	1	2011	Yes	No	31	No
29	M	30	OGU, E, S, GIT, J, CNS	Pred, MMF, CyA, Tac, TNF	64	1	2011	Yes	Yes	9	No
30	M	18	OGU, E, J, Vasc	Pred, MMF, CyA, CYC, Col, TNF	82	2	2012	Yes	Yes	6	No
31	M	35	OGU, E, S, J	Pred, CyA, Col, TNF	20	2	2012	Yes	No	21	No
32	F	25	OGU, S, CNS	MMF, MTX, TNF, RIT	37	2	2013	Yes	Yes	6	No

Outcome data (remission, relapse and duration of remission) related to the *first* alemtuzumab course. Thyroid disease diagnosed during follow-up time after treatment with alemtuzumab and may relate to other consequent courses. Disease duration: Behçet's Disease duration prior to first alemtuzumab treatment. Duration of remission: time in months from achievement of remission to relapse or last follow-up. ALM: alemtuzumab, OGU: orogenital ulcers, E: eyes, J: joints, CNS: central nervous system, S: Skin, GIT: gastrointestinal tract, Vasc: vascular (including venous thromboembolism), L: Lungs, PNS: peripheral nervous system, K: Kidney, Pred: prednisolone, AZA: Azathioprine. Tac: Tacrolimus, MMF: mycophenolate mofetil, CyA: Cyclosporine A, CYC: Cyclophosphamide, Thal: Thalidomide, IVIG: intravenous immunoglobulin, MTX: Methotrexate, Dap: Dapsone, Hcxq: Hydroxychloroquine, TNF: Anti-tumour necrosis factor, PE: plasma exchange, Col: Colchicine, RIT: Rituximab. Patients 3, 6, 7, 11 and 16 were lost to follow-up at 108, 84, 3, 29, and 66 months, respectively.


SUPPLEMENTARY FIGURES



Supplementary Figure 1. All courses alemtuzumab (50 remissions). Kaplan–Meier curve showing relapse-free survival patients with refractory/relapsing Behçet’s disease after treatment with alemtuzumab (CAMPATH-1H).



Supplementary Figure 2. All first course alemtuzumab (27 remissions). Kaplan–Meier curve showing relapse-free survival patients with refractory/relapsing Behçet’s disease after treatment with alemtuzumab (CAMPATH-1H).



Supplementary Figure 3. All first course (27 remissions) per treatment groups ($p = 0.038$). Kaplan–Meier curve showing relapse-free survival patients with refractory/relapsing Behçet’s disease after treatment with alemtuzumab (CAMPATH-1H).